Picture Berlin Partner Top News Healthtech Company Mika 650x100px
Document › Details

BRAIN Biotech AG. (9/27/22). "Press Release: Change in the Executive Management Board of BRAIN Biotech AG, Genome Editing Activities Established Under the Akribion Genomics brand". Zwingenberg.

Organisations Organisation BRAIN Biotech AG
  Group BRAIN Biotech (Group)
  Organisation 2 Akribion Genomics (genome editing business of BRAIN Biotech AG until 6/23)
  Today Akribion Genomics AG (since 6/23)
  Group BRAIN Biotech (Group)
Products Product genome editing (gene editing)
  Product 2 industrial biotechnology
Persons Person Linnig, Lukas (BRAIN Biotech 202210– Business Head of Akribion Genomics before CFO of BRAIN AG joined 201704)
  Person 2 Schneiders, Michael (BRAIN Biotech 202210– CFO joined 202005 as Head of IR before >20y in investment banking)

> Lukas Linnig stepping down as CFO. Michael Schneiders to become new CFO of BRAIN Biotech AG as of October 1st, 2022

> Lukas Linnig and Dr. Michael Krohn to jointly lead Akribion Genomics activities

> Akribion Genomics established as new brand for the proprietary BRAIN genome editing platform technology

BRAIN Biotech AG has announced that current Chief Financial Officer Lukas Linnig is stepping down as CFO to lead Akribion Genomics, the newly established brand for the highly promising genome editing platform technology of BRAIN Group. Michael Schneiders, currently Head of Investor Relations & Sustainability, will be appointed as the new Chief Financial Officer of BRAIN Biotech AG.

Michael Schneiders has joined the company in May 2020 after more than twenty years in investment banking. He has also been involved in the initial public offering of BRAIN. The personnel changes in the executive management board of BRAIN Biotech AG will become effective as of October 1st, 2022. Linnig will be joined at Akribion Genomics by Dr. Michael Krohn, currently Head R&D BRAIN Biotech. Linnig and Krohn will jointly lead the activities under the brand name to fully capitalize on the great promise that genome editing represents to BRAIN and its customers. It is BRAIN’s stated intention to establish a separate legal entity for Akribion in the next year and to attract significant external growth funding for this venture.

Adriaan Moelker, CEO of BRAIN Biotech AG, says: “Lukas Linnig and Michael Krohn have been essential in leading our genome editing activities over the last years, driven by the great scientific progress made by the R&D team. It is only logical that they will now become the appointed leaders to drive Akribion Genomics towards its stated goals. Michael Krohn will assume his leadership role as soon as his successor takes over the R&D leadership at BRAIN. I am also looking forward to working together with Michael Schneiders on the executive board of BRAIN Biotech AG. Michael has proven IR, financial and business development skills and a well-established capital market track record.”

Dr. Georg Kellinghusen, Chairman of the Supervisory Board of BRAIN Biotech AG, says: "It is a very strong sign of confidence in the business potential of Akribion Genomics that the envisaged spin-out will be led by the high caliber team of Lukas Linnig and Dr. Michael Krohn. I am also happy that we have been able to capitalize on our internal succession planning with Michael Schneiders as the designated CFO of BRAIN Biotech."

Lukas Linnig states: “It has been a great honor for me to serve BRAIN as its CFO. Leading Akribion, I will be focusing my attention on accelerating one of BRAIN’s most important value drivers with transformational potential. I am thrilled to take on this challenge of building a successful business in the genome editing market under the Akribion Genomics brand.”

Dr. Michael Krohn, adds: “I am convinced about the potential of our proprietary genome editing technology, especially since our unique mode of action enables us to offer a very valuable addition to the existing genome editing toolsets.”


BRAIN Biotech AG (“BRAIN”) is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products – BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success.

BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. Our products and services target at least five of the UN SDGs directly.

Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).


This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Contact Media
Dr. Stephanie Konle
+49 6251 9331 70

Head of Investor Relations & Sustainability
Michael Schneiders
+49 6251 9331 86

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for BRAIN Biotech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group World of Partnering Opportunities 650x300px

» top